Diebold Nixdorf, Incorporated DBD
62.72
0.25
0.40%
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 20.2×
Follow DBD
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
27.34 | 25.23 | 25.81 | 41.03 |
+8 more quarters Free account |
P/S ratio |
0.76 | 0.69 | 0.66 | 0.56 | |
P/FCF ratio |
13.80 | 10.44 | 10.45 | 9.07 | |
P/Operating CF |
(215.05) | 83.53 | 11.49 | 55.66 | |
P/B ratio |
3.00 | 2.58 | 2.26 | 1.87 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.93 | 0.83 | 0.79 | 0.74 | |
EV/EBITDA |
9.50 | 8.53 | 8.04 | 8.02 | |
EV/Operating CF |
13.13 | 10.15 | 10.04 | 9.79 | |
EV/FCF |
16.91 | 12.67 | 12.64 | 11.92 | |
Quick Ratio |
0.69 | 0.69 | 0.79 | 0.68 | |
Current Ratio |
1.27 | 1.28 | 1.30 | 1.36 | |
Net Debt/EBITDA |
7.36 | 8.60 | 4.55 | 6.11 | |
Debt/Assets |
25.23% | 24.53% | 24.35% | 25.08% | |
Debt/Equity |
0.97 | 0.92 | 0.85 | 0.84 | |
Asset Turnover |
1.04 | 1.03 | 1.03 | 0.97 | |
Operating CF/Net income |
(0.88) | 6.34 | 4.39 | 0.91 | |
Capex/Depreciation |
(0.47) | (0.33) | (0.67) | (0.39) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2.20% | 2.48% | 1.93% | 2.15% | |
Selling, General and Administrative Expense of Revenue |
17.44% | 17.63% | 15.90% | 15.96% | |
Intangible Assets out of Total Assets |
0.37 | 0.36 | 0.37 | 0.39 | |
Share Based Compensation of Revenue |
0.45% | 0.36% | 0.25% | 0.32% | |
Graham Net Nets |
(0.36) | (0.38) | (0.39) | (0.43) | |
Graham Number |
44.57 | 44.35 | 42.15 | 30.87 | |
Earnings Yield |
3.66% | 3.96% | 3.87% | 2.44% | |
Free Cash Flow Yield |
7.25% | 9.58% | 9.57% | 11.03% | |
Revenue per Share |
27.06 | 25.41 | 30.01 | 25.90 | |
Operating CF per Share |
(0.40) | 0.90 | 5.91 | 1.02 | |
Capex per Share |
(0.44) | (0.31) | (0.59) | (0.35) | |
Free Cash Flow per Share |
(0.84) | 0.59 | 5.32 | 0.67 | |
Cash per Share |
8.21 | 10.64 | 11.32 | 7.67 | |
Shareholders Equity per Share |
28.39 | 29.24 | 30.02 | 30.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.39 | 29.24 | 30.02 | 30.48 | |
Free Cash Flow |
(28.90) | 20.70 | 195.70 | 24.50 | |
Working Capital |
361.00 | 396.10 | 415.30 | 458.30 | |
Capital Expenditures |
(15.30) | (11.00) | (21.80) | (12.90) | |
Net Current Asset Value |
(1,048.30) | (1,003.60) | (962.80) | (889.70) | |
EV/EBIT |
14.56 | 13.11 | 12.48 | 13.62 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.01 | |
Net Profit Margin |
1.67% | 0.56% | 4.49% | 4.35% | |
Price to Operating Income |
11.87 | 10.80 | 10.32 | 10.37 | |
| Other line items | |||||
Average Receivables |
625.80 | 599.80 | 628.65 | 622.75 | |
Average Payables |
468.75 | 466.05 | 445.65 | 470.35 | |
Average Inventory |
584.95 | 553.05 | 524.55 | 620.40 | |
Average Assets |
3,738.25 | 3,727.75 | 3,698.95 | 3,812.55 | |
Average Common Equity |
1,040.75 | 1,008.60 | 1,021.50 | 1,094.15 |
Columns are period end dates